CAJ | 학술논문

目的探讨难治性复发性急性白血病单倍型淋巴细胞输注的疗效.方法 2006年4月至2007年10月应用单倍型淋巴细胞输注治疗复发性急性髓性白血病(AML)3例(M22例,M41例),复发性急性淋巴细胞白血病(ALL)1例,4例复发患者在二线方案化疗无效后,采集供者淋巴细胞,子女供父母3例,母供子1例,供者淋巴细胞在输注前,患者再次接受了不同方案的化疗,白细胞较低时输注供者的淋巴细胞,平均输注细胞2.3(1.4～3.1)×108/kg,输注前淋巴细胞接受了6～8Gy 60Coγ射线照射.结果 3例AML患者1例获得了完全缓解(CR),2例有效,1例ALL无效.4例患者输注单倍型供者淋巴细胞后无移植物抗宿主病的发生,未出现严重的骨髓抑制,1例患者发生了带状疱疹病毒感染.结论单倍型供者淋巴细胞输注配合化疗对难治复发的AML有疗效,输注细胞的数量及照射的剂量需进一步探讨.
목적 탐토난치성복발성급성백혈병단배형림파세포수주적료효.방법 2006년4월지2007년10월응용단배형림파세포수주치료복발성급성수성백혈병(AML)3례(M22례,M41례),복발성급성림파세포백혈병(ALL)1례,4례복발환자재이선방안화료무효후,채집공자림파세포,자녀공부모3례,모공자1례,공자림파세포재수주전,환자재차접수료불동방안적화료,백세포교저시수주공자적림파세포,평균수주세포2.3(1.4～3.1)×108/kg,수주전림파세포접수료6～8Gy 60Coγ사선조사.결과 3례AML환자1례획득료완전완해(CR),2례유효,1례ALL무효.4례환자수주단배형공자림파세포후무이식물항숙주병적발생,미출현엄중적골수억제,1례환자발생료대상포진병독감염.결론 단배형공자림파세포수주배합화료대난치복발적AML유료효,수주세포적수량급조사적제량수진일보탐토.
Objective To evaluate the effect of haploidentical lymphocyte infusion on refractory and relapse acute leukemia. Methods The haploidentical donor lymphocyte infusion was used to treat for relapse acute myeloid leukemia 3 patients (M2 2 eases, M4 lcase), one relapse acute lymphocyte leukemia from April 2006 to October 2007. Four cases who had accepted secondly regimens were ineffective,after relapse. Collecting donor lymphocytes, parents children as donor supply in 3 cases, mother as donor supply one case. Before donor lymphocyte infusion patients received chemotherapy of different regimens. Donor haploidentical iymphocytes irradiated by 6-8 Gy radial were infused when patients white cell count was at the lowest after the chemotherapy. The average of infusion cells was 2.3 (1.4-3.1)×108/kg. Results One patient acquired complete remission and two patients were effective in three relapse acute myeloid leukemia. It was ineffective in relapse acute lymphocyte leukemia. No transfusion related graft versus host disease was observed. One patient has had herpes zoster virus infection. Conclusion Haploidentical donor lymphocyte infusion with chemotherapy are effective for refractory and relapse in acute myeloid leukemia, but the infused cell quantity and irradiated dosage must be further discussed.